Open access

Extended Characterization of Human Uropathogenic Escherichia coli Isolates from Slovenia

Written By

Marjanca Starčič Erjavec and Darja Žgur-Bertok

Submitted: 10 December 2010 Published: 06 September 2011

DOI: 10.5772/24699

From the Edited Volume

Clinical Management of Complicated Urinary Tract Infection

Edited by Ahmad Nikibakhsh

Chapter metrics overview

2,620 Chapter Downloads

View Full Metrics

1. Introduction

Escherichia coli (E. coli) is a very diverse bacterial species found naturally in the intestinal tract of humans and many other animal species. Even though E. coli is known to be part of the normal gut microbiota, some strains – that are pathogenic – cause a wide variety of different intestinal and extraintestinal diseases (Marrs et al., 2005). Typical extraintestinal infections due to E. coli include urinary tract infections (UTI), diverse intra-abdominal infections, pneumonia, surgical-site infection, meningitis, osteomyelitis, soft-tissue infections, bacteremia (Russo & Johnson, 2006).

UTIs are one of the most frequently acquired bacterial infections and E. coli accounts for as many as 90% of all community-acquired UTIs. Approximately 50% of all women have had a UTI by their late 20s. About 20–30% of women with first UTI will have two or more infections; while 5%, will develop chronic recurring infections which greatly disrupt a woman’s life (Marrs et al., 2005). In Slovenia E. coli is the causative agent of approximately 80% of uncomplicated UTIs (Lindič, 2005).

E. coli isolates that cause UTI exhibit a number of specific characteristics and are classified, as uropathogenic E. coli (UPEC), a subgroup of extraintestinal pathogenic E. coli (ExPEC) (Russo & Johnson, 2000). UPEC strains mainly belong to the B2 phylogenetic group and to a lesser extent to the D group, while commensal strains belong to groups A and B1 (Picard et al., 1999). Further, some O-antigens (O1, O2, O4, O6, O7, O18 and O83) are more prevalent among uropathogenic E. coli strains and are therefore associated with UTI (Moreno et al. 2006). In comparison to commensal E. coli strains, UPEC possess an array of virulence factors namely, adhesins, toxins, polysaccharide coatings, invasins, iron uptake systems and systems to evade host immune responses (Oelschlaeger et al., 2002).

Of serious concern and an increasing health problem, on a global scale, is the appearance and spread of antimicrobial resistance. One of the major health care concerns is emergence of multidrug resistant bacteria and clinical microbiologists increasingly agree that multidrug resistant Gram-negative bacteria pose the greatest risk to public health (Kumarasamy et al., 2010). Therefore, it is essential to determine susceptibility of pathogenic strains for antimicrobial agents and association of antimicrobial resistance with virulence genes.

One of the means for acquiring specific virulence factor genes and antimicrobial resistance genes, is via mobile DNA (e. g. conjugal plasmids, transposons/integrons) (Alekshun & Levy, 2007; Boerlin & Reid-Smith, 2008; Dobrindt et al., 2010). Hence, determining the prevalence of mobile elements and examining the correlation of antimicrobial resistance/virulence factor genes with mobile elements among UPEC is of great significance.

The search for alternative antibacterial agents is of great importance and colicins, toxic, narrow killing spectrum exhibiting proteins produced by colicinogenic E. coli, exhibit great potential as an alternative approach in the battle against microbes. It has been reported that colicins are effective against intestinal and UPEC strains (Rijavec et al., 2007; Schamberger et al., 2004; Stahl et al., 2004), and that they prevent colonization of urinary catheters (Trautner et al., 2005). To evaluate the potential of colicins as antimicrobial agents, studies on the prevalence of colicins and colicin resistance are needed.

In summary, to diminish the burden of UPEC, using effective preventive measures, data on phylogenetic groups, serogroups, virulence factor prevalence, antimicrobial resistance, presence of mobile DNA, colicin production and colicin resistance among E. coli isolates from different geographic regions must be assessed.

In Slovenia in 2002, we collected 110 E. coli isolates from humans with community-acquired urinary tract infections at the Institute of Microbiology and Immunology, Medical Faculty, Ljubljana, Slovenia. Isolation was performed according to standard laboratory protocols and UPEC were isolates from > 105 colony-forming units (CFU) (Rijavec et al., 2006). These isolates were studied in order to obtain an extended characterisation, including phylogenetic groups, serogroups, virulence factor prevalence, antimicrobial resistance, presence of mobile DNA and colicinogeny and colicin resistance (Rijavec et al., 2006; Starčič Erjavec et al., 2006; Starčič Erjavec et al., 2007; Starčič Erjavec & Žgur-Bertok, 2008; Starčič Erjavec et al., 2008; Starčič Erjavec et al., 2009; Starčič Erjavec et al., 2010).

Advertisement

2. Phylogenetic groups and subgroups

E. coli strains can be assigned to one of four main phylogenetic groups: A, B1, B2, and D. The four groups were identified on the basis of allelic variation at enzyme-encoding genes detected by multilocus enzyme electrophoresis (Ochman et al., 1983, Whittam et al., 1983). Clermont et al. (2000) established the method of rapid and simple determination of the E. coli phylogenetic groups by a triplex PCR. This genotyping method is based on the amplification of a 279 bp fragment of the chuA gene; a 211 bp fragment of the yjaA gene; and a 152 bp fragment of TSPE4.C2, a noncoding region of the genome. The presence or absence of combinations of these three amplicons is used to assign E. coli to one of the four phylogenetic groups. However, to increase the discriminative power of phylogenetic group analysis, Escobar-Paramo et al. (2004) proposed the introduction of phylogenetic subgroups. They defined (Figure 1), apart from the phylogenetic group B1 (lacking chuA and yjaA and having Tspe4.C2), the following six subgroups: in the phylogenetic group A, subgroupA0 (lacking chuA, yjaA, and Tspe4.C2) and subgroup A1 (lacking chuA, having yjaA, and lacking Tspe4.C2); in the phylogenetic group B2, subgroup B22 (having chuA and yjaA and lacking Tspe4.C2) and subgroup B23 ( having chuA, yjaA, and Tspe4.C2); in the phylogenetic group D, subgroup D1 (having chuA and lacking yjaA and Tspe4.C2) and subgroup D2 (having chuA, lacking yjaA, and having Tspe4.C2), Fig. 1.

Analysis of our collection of 110 UPEC isolates showed that 55 (50%) belonged to group B2, 28 (25%) to A, 21 (19%) to D, and 6 (5%) to the B1 group (Rijavec et al., 2006). When subgroups were considered the distribution of the isolates was: 4 (4%) of the studied isolates belonged to the subgroup A0, 24 (22%) to A1, 6 (5%) to B22, 49 (45%) to B23, 16 (15%) to D1 and 5 (5%) to D2 (our unpublished data).

Figure 1.

Diagram of phylogenetic (sub)group determination.

The obtained distribution of the studied isolates into the phylogenetic groups, with the large majority classifying to the B2 group was expected since, it is known that ExPEC isolates mainly belong to the B2 phylogenetic group (Picard et al., 1999) however, the disproportionate distribution into the B22 (5%) and B23 (45%), and A0 (4%) and A1 (22%) subgroups was surprising.

Advertisement

3. Serogroups

Serotyping of E. coli isolates is an often used method for distinguishing possible pathogenic E. coli from commensal E. coli. It is complex since among E. coli 173 O-antigens, 80 K-antigens, and 56 H-antigens can be found. The O-, K-, and H-antigens can occur in many possible combinations therefore, the final number of E. coli serotypes is very high, 50,000-100,000 or more. However, the number of frequent pathogenic serotypes is limited. Two main groups of frequent serotypes are: (i) serotypes from diarrhoeal disease and (ii) serotypes from extraintestinal disease (Orskov & Orskov, 1992).

Serotyping of the 110 uropathogenic strains revealed that 77 (70%) were O-antigen typable, 19 (17%) were O-nontypable, and 14 (12.7%) were rough. Sixty-three (57%) of the examined strains were H-antigen typable, 41 (37%) were H-antigen negative, and 6 (5%) were H-antigen nontypable. The O-typable strains were distributed into 31 serogroups. Nevertheless, the most frequent were O2 (9 isolates) and serotype O6:H1 (10 isolates). Five common serotypes were identified in three or more strains: O2:HNT (n = 3), O2:H6 (n = 3),

O6:H1 (n = 10), O7:HNT (n = 3), and O74:H39 (n = 4) accounting for 30% of the serotypable isolates. A number of other serotypes were detected in one or two strains (Rijavec et al., 2006).

Serotype analysis of the studied strains revealed that they belonged to diverse serogroups. However, the most frequent were O2 and O6, which are well established as associated with urinary tract infections. The large majority, 96%, of the O2 and O6 isolates were assigned to the B2 phylogenetic group (Rijavec et al., 2006).

Advertisement

4. Virulence factors

Any component of a microbe that is required for, or potentiates its ability to cause disease is designated as a virulence factor. Many different virulence factors exist however, they can all be placed in one of the four major groups of virulence factors: adhesins, toxins, iron uptake systems and host immunity evading systems. Hence, virulence factors facilitate colonization and invasion of the host, avoidance or disruption of host defence mechanisms, injury to host tissue, and/or stimulation of a noxious host inflammatory response (Johnson and Steel, 2000).

4.1. Adhesins

Among the first virulence factors that come into play during establishment of an infection are adhesins. Besides their primary role as adhesin molecules, they can also function as invasins, promoters of biofilm formation and transmitors of signals to epithelial cells resulting in inflammation. Various adhesins have been identified and studied (Zhang & Foxman, 2003). In our analysis we focused on the four mostly studied: type 1 fimbriae, P fimbriae, S fimbriae and the Afa/Dr family of adhesins (Starčič Erjavec & Žgur-Bertok, 2008).

Type 1 fimbriae are the most common adhesive organelles of E. coli strains. They are encoded by the vast majority of uropathogenic E. coli (UPEC) isolates and many other pathogenic and commensal isolates (Bower et al., 2005). Receptors for type 1 fimbriae are present on erythrocytes, buccal epithelial cells, intestinal cells, vaginal cells and uroepithelial cells (Johnson, 1991). The fimH gene that was tested in our study (Starčič Erjavec & Žgur-Bertok, 2008), encodes the minor subunit protein FimH that mediates binding to the receptor. FimH has several variants: UPEC strains have a FimH that binds both monomannose and trimannose containing glycoprotein receptors, while commensal E. coli isolates typically show high affinity binding to only trimannose residues (Bower et al., 2005). Type 1 fimbriae function not just as adhesins, but also as invasins for bladder epithelial cells (Martinez et al., 2000).

P fimbriae are among the best studied fimbrial adhesive fibres of UPEC strains. The P fimbrial adhesin molecule (PapG) recognizes globoseries of glycolipids as receptors (Zhang & Foxman, 2003). In our study the papC, papGII and papGIII genes were included (Starčič Erjavec & Žgur-Bertok, 2008). The papC gene encodes the outer membrane usher protein that is required for ordered P fimbriae assembly (Thanassi et al., 1998). Many studies showed that P fimbriae occur more frequently among UPEC than fecal isolates. Based on binding specificities, P fimbriae are grouped into three major classes: I, II and III (Zhang & Foxman, 2003).

S fimbriae bind to sialyl galactosides. Studies showed that E. coli UTI isolates were at least two times more likely to carry S fimbriae genes (sfa operon) than fecal strains (Zhang & Foxman, 2003). In our study the fimbriae typical gene sequence sfa/foc was investigated (Starčič Erjavec & Žgur-Bertok, 2008).

The Afa/Dr family consists of 13 known adhesins that all bind to the Dra blood group antigen present on the complement regulatory molecule CD55, also known as decay-accelerating factor (DAF) (Bower et al., 2005). The E. coli strains harbouring these adhesins have been found to be associated with UTIs and also with various enteric infections (Servin, 2005).

Among the tested adhesin genes in the studied UPEC isolates (Table 1), the type 1 fimbriae were the most prevalent - the fimH gene nucleotide sequences were detected in 107 strains (97%). The P fimbriae were also abundant, the papC encoding gene sequence was found in 54 strains (49%), 37 strains (34%) harboured the class II papG adhesin sequence and 14 strains (13%) harboured the class III papG adhesin. Twenty-six (24%) possessed the S fimbriae typical gene sequence sfa/foc. Only 2 strains (2%) harbored afa/dra sequences (Starčič Erjavec & Žgur-Bertok, 2008).

Analysis of the distribution of adhesin gene sequences among phylogenetic groups revealed that adhesin gene sequences were differently distributed (Table 1): fimH sequences were found with similar prevalence in strains of all four phylogenetic groups, papC sequences were found in all phylogenetic groups, but they were most prevalent (65%) among B2 group strains. The association of papC with the B2 group was statistically significant. Nevertheless, papGII sequences were found in all phylogenetic groups, in contrast, papGIII adhesin sequences were exclusively found among strains of the B2 group.

Further, a very high, statistically significant, prevalence of S fimbriae in the B2 group was detected, 45% of the strains belonging to the B2 group harboured sfa/foc sequences (Starčič Erjavec & Žgur-Bertok, 2008).

4.2. Toxins

Toxins affect an astonishing variety of fundamental eukaryotic processes and thereby harm the host (Kaper, 2004) and are important virulence factors in a variety of E. coli mediated diseases – in UTI the production of toxins by colonized E. coli may cause an inflammatory response that leads to the UTI symptoms (Zhang & Foxman, 2003).

In pathogenic E. coli strains several important toxins have been identified, the best known, associated with UPEC strains, are alpha hemolysin (HlyA) and cytotoxic necrotizing factor 1 (CNF1) (Zhang & Foxman, 2003).

Well known toxins are also invasins, the Ibe proteins that help E. coli strains to invade the human brain microvascular endothelial cells (Xie et al., 2004). The presence of IbeA protein is statistically significantly higher in strains causing cystitis and/or pyelonephritis (Johnson et al., 2005). The gene for the uropathogenic specific protein (USP) that was found as a homologue of the Vibrio cholerae zonula occludens toxin encoding gene (Kurazono et al., 2000), has been significantly more often detected in UPEC strains than in fecal strains from healthy individuals (Bauer et al., 2002).

Among the screened toxin encoding genes in the studied UPEC isolates (Table 1), the usp gene had the highest prevalence as usp specific nucleotide sequences were detected in 48 strains (44%). The prevalence of hlyA and cnf1 was similar, 28 (25%) and 25 strains (23%), respectively, possessed the tested nucleotide sequences. Only 10 strains (9%) harboured ibeA sequences (Starčič Erjavec et al., 2008).

Analysis of the distribution of toxin encoding genes among the determined phylogenetic groups of studied strains (Table 1) revealed that the tested toxin encoding genes hlyA, cnf1, ibeA and usp were mostly harboured by UPEC strains belonging to the B2 phylogenetic group, as 26 (93%) of the strains harbouring hlyA belonged to the B2 group, 25 (100%) harbouring cnf1, 9 (90%) harbouring ibeA and 42 (88%) harbouring usp belonged to the B2 phylogenetic group (Starčič Erjavec et al., 2008).

Prevalence (N, [%])
Phylogenetic group
TraitTotal
(N=110)
A
(N=28)
B1
(N=6)
B2
(N=55)
D
(N=21)
Virulence factors
Adhesins
fimH107 (97)28 (26)5 (5)53 (50)21 (20)
papC54 (49)8 (15)1 (2)35 (65)10 (19)
papGII37 (34)5 (14)1 (3)21 (57)10 (27)
papGIII14 (13)0 (0)0 (0)14 (100)0 (0)
sfa/foc26 (24)1 (4)0 (0)25 (96)0 (0)
afa/dra2 (2)1 (50)0 (0)1 (50)0 (0)
Toxins
hlyA28 (25)1 (4)0 (0)26 (93)1 (4)
cnf25 (23)0 (0)0 (0)25 (100)0 (0)
ibeA10 (9)0 (0)0 (0)9 (90)1 (10)
usp48 (44)1 (2)0 (0)42 (88)5 (10)
Iron uptake systems
iucD46 (42)8 (17)0 (0)27 (59)11 (24)
iroCD (=iroN)51 (46)9 (18)0 (0)41 (80)1 (2)
ireA22 (20)4 (18)0 (0)12 (55)6 (27)
fyuA84 (76)17 (20)3 (4)49 (58)15 (18)
Host immunity evading systems
K16 (5)1 (17)1 (17)4 (67)0 (0)
K511 (10)2 (18)1 (9)8 (73)0 (0)
traT63 (57)20 (32)4 (6)29 (46)10 (16)
tcpC23 (21)0 (0)0 (0)23 (100)0 (0)
Antimicrobial susceptibility
Ampicillin57 (52)12 (21)5 (9)32 (56)18 (32)
Ciprofloxacin99 (90)23 (23)5 (5)52 (53)19 (19)
Chloramphenicol50 (45)7 (14)3 (6)32 (64)8 (16)
Kanamycin95 (86)20 (21)5 (5)51 (54)19 (20)
Mezlocillin59 (54)12 (20)5 (8)34 (58)8 (14)
Nalidixic acid64 (58)12 (19)3 (5)38 (59)11 (17)
Norfloxacin99 (90)23 (23)5 (5)52 (52)19 (19)
Streptomycin69 (63)15 (22)5 (7)40 (60)9 (13)
Sulfamethoxazole-Trimethoprim87 (79)18 (21)6 (7)49 (56)14 (16)
Tetracycline47 (43)6 (13)4 (9)33 (70)4 (9)
Trimethoprim72 (65)14 (19)6 (8)41 (57)11 (15)
Mobile genetic elements
RepFIA20 (18)7 (35)0 (0)10 (50)3 (15)
RepFIB57 (52)18 (32)2 (4)26 (46)11 (19)
RepFIIA24 (22)7 (29)0 (0)15 (63)2 (8)
Integron34 (31)12 (35)1 (3)12 (35)9 (26)
Colicinogenity42 (38)12 (29)3 (7)20 (48)7 (17)

Table 1.

Characterized traits in studied UPEC isolates – prevalence and distribution among phylogenetic groups.

4.3. Iron uptake systems

Iron is an essential cofactor for many basic metabolic pathways and bacteria have developed specialized iron uptake systems to capture iron. The most prominent are the siderophores, iron-binding molecules that are taken up by special siderophore receptors and ATP-consuming porin-like transporters in the bacterial outer membrane (Schaible & Kaufmann, 2004). Siderophores can be classified into three groups: (i) the catecholate type (enterobactin, salmochelin = enterochelin), (ii) hydroxamate type (aerobactin) and (iii) a mixed type - a combination of both (yersiniabactin) (Grass, 2006; Schaible & Kaufmann, 2004). In addition to siderophore synthesis strains can use siderophores produced and released into the extracellular medium by other bacteria and even fungi. In the host, bacteria may use iron sources such as heme, hemoglobin, hemopexin, and iron bound to transferrin and lactoferrin (Braun & Braun, 2002). Apart from the siderophores and their receptors, autotransporters, virulence-associated proteins in gram-negative bacteria, can also play a role in obtaining iron for example, the hemoglobin protease Hbp (Otto et al., 2002). All autotransporter proteins are energy-independent secreted via a type 5 secretion system and possess an overall unifying structure, comprising (i) an amino-terminal leader peptide (for secretion across the inner membrane), (ii) the secreted mature protein (or passenger domain), and (iii) a dedicated C-terminal domain, which forms a pore in the outer membrane through which the passenger domain passes to the cell surface (Henderson & Nataro, 2001).

In our study the following iron uptake systems genes were investigated (Table 1): iucD for aerobactin, iroCD and iroN for salmochelin, fyuA for yersiniabactin and ireA of a putative TonB-dependent siderophore receptor. The iron uptake system with the highest prevalence was yersiniabactin, the fyuA gene coding for the ferric yersiniabactin receptor was found in 84 strains (76%). The salmochelin uptake system genes iroN, coding for the catecholate siderophore receptor, and iroCD coding for proteins needed in salmochelin transport, were found in 51 (46%) of studied strains. The aerobactin iron uptake system gene iucD, coding for lysine:N6-hydroxylase needed in aerobactin biosynthesis, was detected in 46 strains (42%) and the ireA gene was harboured by 22 studied strains (20%) (our unpublished data).

Analysis of the distribution of iron uptake systems encoding genes among the determined phylogenetic groups of studied strains (Table 1) revealed that all of the studied iron uptake systems were mostly harboured by UPEC strains belonging to the B2 phylogenetic group, as 41 (80%) of the strains harbouring iroCD and iroN belonged to the B2 group, 49 (58%) harbouring fyuA, 27 (59%) harbouring iucD and 12 (55%) harbouring ireA belonged to the B2 phylogenetic group (our unpublished data).

4.4. Host immunity evading systems

Pathogenic microbes avoid host defences using a wide array of virulence factors, ranging from polysaccharide capsules, serum resistance proteins to immune system modulating agents (Kaper et al., 2004).

Capsules are the discrete structural layers of extracellular polysaccharides that envelope the cell and allow the bacteria to evade or counteract the host immune system (Roberts, 1996). Capsules protect pathogens from assaults such as opsonophagocytosis and complement-mediated killing (Roberts, 1995); and in case of acidic capsules they can act as “sponges” to sequester and neutralize antimicrobial peptides (Llobet et al., 2008). Virtually all UPEC have a K-type polysaccharide capsule. Most UPEC express Group 2 or 3 capsules on their surfaces (Goller and Seed, 2010) and the K-antigens K1, K5, K30 and K92 are the most prevalent among UPEC (Johnson, 1991).

TraT, the surface exclusion protein of the plasmid transfer system, has been implicated in increased serum resistance (Binns et al., 1979). TraT is one of the most prevalent virulence factors in pathogenic E. coli isolates, as traT sequences have been found in 50% of E. coli isolates from sepsis (Ananias & Yano, 2008), in 68% of uroseptic E. coli (Johnson & Stell, 2000), and in 65% of UPEC isolates from cystitis, pyelonephritis, prostatitis (Johnsons et al., 2005a).

Recently, TcpC, a Toll/interleukin-1 receptor (TIR) domain–containing protein of uropathogenic E. coli inhibiting Toll-like receptor (TIR) and MyD88-specific signaling, impairing the innate immune response was described (Cirl et al, 2008). The tcpC homologous sequences were found in about 40% of E. coli isolates from individuals with pyelonephritis, in 21% cystitis isolates, in 16% asymptomatic bacteriuria and in only 8% of commensal isolates therefore, TcpC is implicated in the severity of urinary tract infections (UTI) in humans (Cirl et al., 2008).

Among the 110 studied UPEC isolates (Table 1) 6 (5%) had the K1-capsule and 11 (10%) had the K5-capsule (Starčič Erjavec et al., 2007). The traT sequences were found in 63 (57%) (Rijavec et al., 2006) and the tcpC sequences were found in 23 (21%) (Starčič Erjavec et al., 2010) of studied UPEC isolates.

Analysis of the distribution of the studied immune system evading characteristics among the determined phylogenetic groups (Table 1) showed that, isolates with K1- and K5-capsules were the most prevalent in the B2 group, 4 (67%) and 8 (73%), respectively however, capsule possessing isolates also belonged to the A and B1 group, albeit at low prevalence. One (17%) K1-capsule coated strain was found in the A and one in the B1 group and 2 (18%) K5-capsule coated strains in the A group and one (9%) in the B1 group. The traT sequence was more evenly distributed among all four phylogenetic groups A, B1, B2 and D – the prevalence was 20 (32%), 4 (6%), 29 (46%) and 10 (16%), respectively. On the other hand, the tcpC-encoding strains were found only in the B2 group.

Advertisement

5. Antimicrobial susceptibility

An important task in clinical microbiology is the performance of antimicrobial susceptibility testing in order to detect possible drug resistance in common pathogens and to assure susceptibility to drugs of choice for particular infections (Jorgensen & Ferraro, 2009). Therefore, several studies on the subject of antimicrobial susceptibility and E. coli isolates from UTI have been performed (e. g. Karlowsky et al., 2003; Kahlmeter & Menday, 2003; Yilmaz et al., 2009).

In the year 2002, when the studied isolates were collected, treatment of UTI in outpatients in Slovenia was as follows: a course of antibiotics (therapy of choice - trimethoprim 160 mg or trimethoprim/sulfamethoxazole 160 mg/800 mg twice daily for 3 days) and advice to consume sufficient quantities of liquids (2–3 l per day) (Car et al., 2003).

The studied uropathogenic strains were screened for susceptibility to the following antibiotics: ampicillin, chloramphenicol, kanamycin, streptomycin, tetracycline, trimethoprim, trimethoprim-sulfamethoxazole, ciprofloxacin, norfloxacin, nalidixic acid, mezlocillin, amikacin, cefotaxime, cefotiame, cefoxitin, ceftazidime, and gentamicin. Susceptibilities to the tested antibiotics ranged from 109 (99%) susceptible to amikacin, cefotaxime, ceftazidime, to 47 (43%) susceptible to tetracycline. Antibiotics with the highest prevalence of susceptibility, apart from amikacin, cefotaxime, ceftazidime, were to cefotiame, cefoxitin, and gentamicin as 108 (98%), 103 (94%), and 101 (92%) of the studied strains, respectively, were susceptible. Antibiotics with the lowest prevalence of susceptibility, apart from tetracycline, were to chloramphenicol, ampicilin, mezlocillin and nalidixic acid, as 50 (45%), 57 (52%), 59 (54%) and 64 (58%), respectively, were susceptible (Rijavec et al., 2006).

Forty-six (42%) of the studied strains were resistant to more than three classes of the tested antimicrobial agents—beta lactams, quinolone/fluoroquinolone, trimethoprim/ trimethoprim-sulfamethoxazole, tetracycline, chloramphenicol, aminoglycosides (streptomycin, kanamycin)—and were designated as multidrug resistant (MDR). Subsequently, the association between MDR and the phylogenetic group was examined. A statistically significant correlation between non-MDR and the B2 group was determined and a significant correlation between MDR and the D phylogenetic group was found. On the other hand, there were no statistically significant correlations between MDR or non-MDR strains and the A or B1 groups (Rijavec et al., 2006).

Advertisement

6. Mobile genetic elements

The loss and gain of mobile genetic elements has a pivotal role in shaping the genomes of pathogenic bacteria. Horizontal gene transfer is an important mechanism that rapidly disseminates new traits to recipient organisms. Acquiring these new traits is crucial in promoting the fitness and survival of a pathogen while it coevolves with its host (Croxen & Finlay, 2010).

Bacterial plasmids, self-replicating, extrachromosomal elements are key agents of change in microbial populations. They promote the dissemination of a variety of traits, including virulence, enhanced fitness, resistance to antimicrobial agents, and metabolism of rare substances (Johnson & Nolan, 2009). E. coli strains possess a variety of plasmid types, of different sizes, usually ranging in size from approximately 300 bp to 2400 kbp nevertheless, each plasmid must harbour a replication region (Kado, 1998). Plasmids are classified into incompatibility groups mostly on the basis of the replication region (Couturier et al., 1988).

Integrons are assembly platforms that incorporate exogenous open reading frames by site-specific recombination and convert them to functional genes by ensuring their correct expression. Integrons are composed of three key elements necessary for the capture of exogenous genes: a gene (intI) encoding an integrase belonging to the tyrosine-recombinase family; a primary recombination site (attI); and an outward-orientated promoter (Pc) that directs transcription of the captured genes. At present, five classes of mobile integrons are distinguished. These classes have been historically defined based on the sequence of the encoded integrases, which show 40–58% identity. All five classes are physically linked to mobile DNA elements, such as insertion sequences, transposons and conjugative plasmids, all of which can serve as vehicles for intraspecies and interspecies transmission of genetic material. Class 1 integrons are associated with functional and non-functional transposons derived from Tn402 that can be embedded in larger transposons, such as Tn21. Class 2 integrons are exclusively associated with Tn7 derivatives and class 3 integrons are thought to be located in a transposon inserted in a plasmid. The other two classes of mobile integrons, class 4 and class 5, have been associated only with Vibrio species; class 4 is a component of a subset of SXT elements found in Vibrio cholerae, and class 5 is located in a compound transposon carried on a plasmid in Vibrio salmonicida (Mazel, 2006).

The studied UTI strains were screened for replication regions of IncFI and IncFII plasmids. We found (Table 1) a high (62 strains, 56%) incidence of rep IncF sequences among the examined UPEC strains. Particularly prevalent were RepFIB sequences that were detected in 57 (52%) of the strains while RepFIA and RepFIIA were found in 20 (18%) and 24 (22%) strains, respectively. rep sequences were found in all four phylogenetic groups. Of the 62 isolates harbouring at least one of the tested IncF replicons, 20 belonged to group A, 2 to B1, 27 to B2, and 13 to group D (Rijavec et al., 2006).

Since only class 1, 2 and 3 of integrons were shown to be associated with pathogenic E. coli in our study we focused only on these three classes. Analysis (Table 1) revealed that 29 (26%) of the strains harboured a class 1 integron, 1 strain (1%) contained a class 1 and a class 2 integron, and 4 strains (4%) a class 2 integron. Analysis of the distribution of integrons with regard to the phylogenetic group showed that integron sequences were found in all four groups. Of the 34 isolates harbouring integron sequences, 12 belonged to group A, 1 to B1, 12 to B2, and 9 to group D (Rijavec et al., 2006).

Advertisement

7. Colicins

Colicins are bacteriocins produced by E. coli strains. As other bacteriocins, colicins are extracellular bacterial toxic proteins that are active against the same, or closely related species as the producer cell (Daw & Falkiner, 1996). The mechanism of action of these compounds involves adsorption to specific receptors located on the external surface of sensitive bacteria followed by killing via one of three primary mechanisms: i) formation of channels in the cytoplasmic membrane, ii) degradation of cellular DNA or iii) inhibition of protein synthesis (Riley & Gordon, 1999). Because of their narrow range of activity, it has been proposed that the primary role of bacteriocins is to mediate intraspecific, or population level, interactions (Riley, 1998) however, bacteriocins have also been implicated in virulence determination, since many pathogenic strains harbour plasmid-encoded bacteriocins, for example the ColV plasmid of UPEC isolates (Johnson & Nolan, 2009). Typically, 25–50% of E. coli isolates are colicinogenic and usually, the percentages are higher among pathogenic than commensal strains (Riley & Gordon, 1996). Due to high levels of colicinogenity in natural E. coli populations, high levels of colicin resistance are known to occur (Feldgarden & Riley, 1998).

Figure 2.

A colicinogenic uropathogenic strain was stab inoculated on 4 points on an agar plate and overlaid with a sensitive E. coli strain.

Among the studied UPEC isolates 42 (38%) exhibited colicinogenic activity (Starčič Erjavec et al., 2006). Each of the 110 UPEC strains was resistant to at least 3 colicinogenic strains from Pugsley's collection of colicinogenic strains (Pugsley & Oudega, 1987), 23 UPEC strains (21%) were resistant to all 20 tested Pugsley's strains (our unpublished data). Colicinogenic strains were found in all four phylogenetic groups (Table 1) however, most colicinogenic strains, 20 (48%) belonged to the B2 group (our unpublished data).

Advertisement

8. Conclusion

Our investigation of UPEC isolates from Slovenia revealed a high prevalence of drug resistance and multidrug resistance. The virulence profile of the examined strains was comparable to that of strains from other geographic regions.

Advertisement

Acknowledgments

This work was supported by the by grant P1-0198 from the Slovenian Research Agency.

References

  1. 1. AlekshunM. N.LevyS. B.2007Molecular mechanisms of antibacterial multidrug resistance. Cell, 1286March 2007), 103710500092-8674
  2. 2. AnaniasM.YanoT.2008Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis. Brazilian Journal of Medical and Biological Research, 4110October 2008), 8778830010-0879X
  3. 3. BauerR. J.ZhangL.FoxmanB.SiitonenA.JantunenM. E.SaxenH.MarrsC. F.2002Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection- usp, iha and iroN(E. coli). The Journal of Infectious Diseases, 18510May 2002), 152115240022-1899
  4. 4. BinnsM. M.DaviesD. L.HardyK. G.1979Cloned fragments of the plasmid ColV,I-K94 specifying virulence and serum resistance. Nature, 2795716June 1979), 7787810028-0836
  5. 5. BoerlinP.Reid-SmithR. J.2008Antimicrobial resistance: its emergence and transmision. Animal Health Research Reviews, 92December 2008), 1151261466-2523
  6. 6. BowerJ. M.EtoD. S.MulveyM. A.2005Covert operations of uropathogenic Escherichia coli within the urinary tract. Traffic 61January 2005), 18311398-9219
  7. 7. BraunV.BraunM.2002Iron transport and signaling in Escherichia coli. FEBS Letters, 5291October 2002), 78850014-5793
  8. 8. CarJ.ŠvabI.KersnikJ.VegnutiM.2003Management of lower urinary tract infection in women by Slovene GPs. Family Practice, 204August 2003), 4524560263-2136
  9. 9. CirlC.WieserA.YadavM.DuerrS.SchubertS.FischerH.StappertD.WantiaN.RodriguezN.WagnerH.SvanborgC.MiethkeT.2008Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nature Medicine, 144April 2008), 3994061078-8956
  10. 10. ClermontO.BonacorsiS.BingenE.2000Rapid and simple determination of the Escherichia coli phylogenetic group. Applied and Environmental Microbiology, 6610October 2010), 455545580099-2240
  11. 11. CroxenM. A.FinlayB. B.2010Molecular mechanisms of Escherichia coli pathogenicity. Nature Reviews Microbiology, 81January 2010), 26381740-1526
  12. 12. CouturierM.BexF.BergquistP. L.MaasW. K.1988Identification and classification of bacterial plasmids. Microbiological Reviews, 523September 1988), 3753950146-0749
  13. 13. DawM. A.FalkinerF. R.1996Bacteriocins: nature, function and structure. Micron : The International Research and Review Journal for Microscopy, 276December 1996), 4674790968-4328
  14. 14. DobrindtU.ChowdaryM. G.KrumbholzG.HackerJ.2010Genome dynamics and its impact on evolution of Escherichia coli. Medical Microbiology and Immunology, 1993August 2010), 1451540300-8584
  15. 15. Escobar-ParamoP.GrenetK.Le Menac’hA.RodeL.SalgadoE.AmorinC.GouriouS.PicardB.RahimyM. C.AndremontA.DenamurE.RuimyR.2004Large-scale population structure of human commensal Escherichia coli isolates. Applied and Environmental Microbiology, 709September 2004), 569857000099-2240
  16. 16. FeldgardenM.RileyM. A.1998High levels of colicin resistance in Escherichia coli. Evolution, 525October 1998), 127012760014-3820
  17. 17. GollerC. C.SeedP. C.2010Revisiting the Escherichia coli polysaccharide capsule as a virulence factor during urinary tract infection: contribution to intracellular biofilm development. Virulence, 14July-August 2010), 3373372150-5594
  18. 18. GrassG.2006Iron transport in Escherichia coli: all has not been said and done. Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine, 192April 2006), 1591720966-0844
  19. 19. HendersonI. R.NataroJ. P.2001Virulence functions of autotransporter proteins. Infection and Immunity, 693March 2001), 123112430019-9567
  20. 20. JohnsonJ. R.1991Virulence factors in Escherichia coli urinary tract infection. Clinical Microbiology Reviews 41January 1991), 801280893-8512
  21. 21. JohnsonJ. R.StellA. L.2000Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. The Journal of Infectious Diseases, 1811January 2000), 2612720022-1899
  22. 22. JohnsonJ. R.KuskowskiM. A.GajewskiA.SotoS.HorcajadaJ. P.Jimenez deAnta. M. T.VilaJ.2005aExtended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. The Journal of Infectious Diseases, 1911January 2005), 46500022-1899
  23. 23. JohnsonJ. R.OwensK.GajewskiA.KuskowskiM. A.2005Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women. Journal of Clinical Microbiology, 4312December 2005), 606460720095-1137
  24. 24. JohnsonT. J.NolanL. K.2009Pathogenomics of the virulence plasmids of Escherichia coli. Microbiology and Molecular Biology Reviews : MMBR, 734December 2009), 7507741092-2172
  25. 25. JorgensenJ. H.FerraroM. J.2009Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 4911December 2009), 174917551058-4838
  26. 26. KadoC. I.1998Origin and evolution of plasmids. Antonie Van Leeuwenhoek, 731January 1998), 1171260003-6072
  27. 27. KahlmeterG.MendayP.2003Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. The Journal of Antimicrobial Chemotherapy, 521July 2003), 1281310305-7453
  28. 28. KaperJ. B.NataroJ. P.MobleyH. L. T.2004Pathogenic Escherichia coli. Nature Reviews Microbiology, 22February, 2004), 1231401740-1526
  29. 29. KarlowskyJ. A.ThornsberryC.JonesM. E.SahmD. F.2003Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 362January 2003), 1831871058-4838
  30. 30. KumarasamyK. K.TolemanM. A.WalshT. R.BagariaJ.ButtF.BalakrishnanR.ChaudharyU.DoumithM.GiskeC. G.IrfanS.KrishnanP.KumarA. V.MaharjanS.MushtaqS.NoorieT.PatersonD. L.PearsonA.PerryC.PikeR.RaoB.RayU.SarmaJ. B.SharmaM.SheridanE.ThirunarayanM. A.TurtonJ.UpadhyayS.WarnerM.WelfareW.LivermoreD. M.WoodfordN.2010Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases, 109September 2010), 5976021473-3099
  31. 31. KurazonoH.YamamotoS.NakanoM.NairG. B.TeraiA.ChaicumpaW.HayashiH.2000Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein. Microbial Pathogenesis, 283March 2000), 1831890882-4010
  32. 32. LindičJ.2005Pristop k bolniku z okužbo sečil.[Accession to a patient with urinary tract infection]. In: Zbornik prispevkov /47. Tavčarjevi dnevi. [Proceedings / 47th Tavčar’s days., Z Fras & P. Poredoš, (Eds.), 137148University of Ljubljana, Medical Faculty, 9-61626-470-2Slovenia
  33. 33. LlobetE.TomásJ. M.BengoecheaJ. A.2008Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology, 154No.Pt 12, (December 2008), 387738861350-0872
  34. 34. MarrsC. F.ZhangL.FoxmanB.2005Escherichia coli mediated urinary tract infections: Are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiology Letters, 2522November 2005), 1831900378-1097
  35. 35. MartinezJ. J.MulveyM. A.SchillingJ. D.PinknerJ. S.HultgrenS. J.2000Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. The EMBO Journal, 1912June 2000), 280328120261-4189
  36. 36. MazelD.2006Integrons: agents of bacterial evolution. Nature Reviews Microbiology, 48August 2006), 6086201740-1526
  37. 37. MorenoE.PratsG.SabateM.PerezT.JohnsonJ. R.AndreuA.2006Quinolone, fluroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropahtogenic Escherichia coli. The Journal of Antimicrobial Chemotherapy, 572February 2006), 2042110305-7453
  38. 38. OchmanH.WhittamT. S.CaugantD. A.SelanderR. K.1983Enzyme polymorphism and genetic population structure in Escherichia coli and Shigella. Journal of General Microbiology, 1299September 1983), 271527260022-1287
  39. 39. OelschlaegerT. A.DobrindtU.HackerJ.2002Virulence factors of uropathogens. Current Opinion in Urology, 121January 2002), 33380963-0643
  40. 40. OrskovF.OrskovI.1992Escherichia coli serotyping and disease in man and animals. Canadian Journal of Microbiology, 387July 1992), 6997040008-4166
  41. 41. OttoB. R.van DoorenS. J.DozoisC. M.LuirinkJ.OudegaB.2002Escherichia coli hemoglobin protease autotransporter contributes to synergistic abscess formation and heme-dependent growth of Bacteroides fragilis. Infection and Immunity, 701January 2002), 5100019-9567
  42. 42. PicardB.GarciaJ. S.GouriouS.DuriezP.BrahimiN.BingenE.ElionJ.DenamurE.1999The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infection and Immunity, 672February 1999), 5465530019-9567
  43. 43. PugsleyA. P.OudegaB.1987Methods for studying colicins and their plasmids, In: Plasmids, a practical approach, K. G. Hardy (Ed.), 105161IRL Press Limited, 0-94794-681-0England
  44. 44. RijavecM.StarčičErjavec. M.AmbrožičAvguštin. J.ReissbrodtR.FruthA.Križan-HergouthV.Žgur-BertokD.2006High prevalence of multidrug resistance and random distribution of mobile genetic elements among uropathogenic Escherichia coli (UPEC) of the four major phylogenetic groups. Current Microbiology, 532August 2006), 1581620343-8651
  45. 45. RijavecM.BudičM.MrakP.Müller-PremruM.PodlesekZ.Žgur-BertokD.2007Prevalence of ColE1-like plasmids and colicin K production among uropathogenic Escherichia coli strains and quantification of inhibitory activity of colicin K. Applied and Environmental Microbiology, 733February 2007), 102910320099-2240
  46. 46. RileyM. A.1998Molecular mechanisms of bacteriocin evolution. Annual Review of Genetics. 322552780066-4197
  47. 47. RileyM. A.GordonD. M.1996The ecology and evolution of bacteriocins. Journal of Industrial Microbiology, 173-4September 1996), 1511580169-4146
  48. 48. RileyM. A.GordonD. M.1999The ecological role of bacteriocins in the bacterial competition. Trends in Microbiology, 73March, 199), 1291330096-6842X
  49. 49. RobertsI. S.1995Bacterial polysaccharides in sickness and in health. The 1995 Fleming Lecture. Microbiology, 141No.Pt 9, (September 1995), 202320311350-0872
  50. 50. RobertsI. S.1996The biochemistry and genetics of capsular polysaccharide production in bacteria. Annual Review of Microbiology, 502853150066-4227
  51. 51. RussoT. A.JohnsonJ. R.2000Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. The Journal of Infectious Diseases, 1815May 2000), 175317540022-1899
  52. 52. RussoT. A.JohnsonJ. R.2006Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Expert Review of Vaccines, 51Februar 2006), 45541476-0584
  53. 53. SchaibleU. E.KaufmannS. H.2004Iron and microbial infection. Nature Reviews Microbiology, 212December 2004), 9469531740-1526
  54. 54. SchambergerG. P.PhillipsR. L.JacobsJ. L.Diez-GonzalezF.2004Reduction of Escherichia coli O157:H7 populations in cattle by addition of colicin E7-producing E. coli to feed. Applied and Environmental Microbiology, 7010October 2004), 605360600099-2240
  55. 55. ServinA. L.2005Pathogenisis of Afa/Dr diffusely adhering Escherichia coli. Clinical Microbiology Reviews, 182April 2005), 2642920893-8512
  56. 56. StahlC. H.CallawayT. R.LincolnL. M.LonerganS. M.GenoveseK. J.2004Inhibitory activities of colicins against Escherichia coli strains responsible for postweaning diarrhea and edema disease in swine. Antimicrobial Agents and Chemotherapy, 488August 2004), 311931210066-4804
  57. 57. StarčičErjavec. M.RijavecM.Žgur-BertokD.2006Colicins of the Escherichia coli uropathogenic strain collection. Acta biologica slovenica, 49213211408-3671
  58. 58. StarčičErjavec. M.RijavecM.Križan-HergouthV.FruthA.Žgur-BertokD.2007Chloramphenicol- and tetracycline-resistant uropathogenic Escherichia coli (UPEC) exhibit reduced virulence potential. International Journal of Antimicrobial Agents, 305November 2007), 4364420924-8579
  59. 59. StarčičErjavec. M.Žgur-BertokD.2008Prevalence, distribution and genetic association of adhesin gene sequences of Escherichia coli isolates from urinary tract infections in Slovenia. Acta biologica slovenica, 51121311408-3671
  60. 60. StarčičErjavec. M.Križan-HergouthV.GubinaB.Žgur-BertokD.2008Prevalence of toxin encoding genes in Escherichia coli isolates from urinary tract infections in Slovenia. Zdravniški vestnik, 6June/July 2008), 4274321318-0347
  61. 61. StarčičErjavec. M.ArbiterT.Žgur-BertokD.2009Pathogenicity islands, plasmids and iron uptake systems in extraintestinal pathogenic Escherichia coli strains. Acta biologica slovenica, 52273831408-3671
  62. 62. StarčičErjavec. M.JesenkoB.PetkovšekŽ.Žgur-BertokD.2010Prevalence and associations of tcpC, a gene encoding a Toll/interleukin-1 receptor domain-containing protein, among Escherichia coli urinary tract infection, skin and soft tissue infection, and commensal isolates. Journal of Clinical Microbiology, 483March 2010), 9669680095-1137
  63. 63. ThanassiD. G.SaulinoE. T.HultgrenS. J.1998The chaporene/usher pathway: a major terminal branch of the general secretory pathway. Current Opinion in Microbiology 12April 1998), 2232311369-5274
  64. 64. TrautnerB. W.HullR. A.DarouicheR. O.2005Colicins prevent colonization of urinary catheters. The Journal of Antimicrobial Chemotherapy, 562August 2005), 4134150305-7453
  65. 65. WhittamT. S.OchmanH.SelanderR. K.1983Multilocus genetic structure in natural populations of Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 806March 1983), 175117550027-8424
  66. 66. XieY.KimK. J.KimK. S.2004Current concepts on Escherichia coli K1 translocation of the blood-brain barrier. FEMS Immunology and Medical Microbiology, 423November, 2004), 2712790928-8244
  67. 67. YilmazN.AgusN.YurtseverS. G.PullukcuH.GulayZ.CoskunerA.KoseS.AydemirS.GulencN.OzgencO.2009Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 1511November 2009), PI61PI651234-1010
  68. 68. ZhangL.FoxmanB.2003Molecular epidemiology of Escherichia coli mediated urinary tract infections. Frontiers in Bioscience, 8January 2003), e235e2441093-9946

Written By

Marjanca Starčič Erjavec and Darja Žgur-Bertok

Submitted: 10 December 2010 Published: 06 September 2011